Omega-3 Fatty Acids (EPA/DHA)

Clinical Summary

Omega-3 fatty acids — primarily eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acid (DHA, 22:6n-3) — are essential polyunsaturated fats that humans cannot synthesize de novo. They incorporate into cell membranes, modulate inflammatory signaling via eicosanoid pathways, and serve as precursors to specialized pro-resolving mediators (resolvins, protectins, maresins) that actively resolve inflammation rather than just blocking it.

The evidence base is among the strongest in supplementation: 120+ PMIDs, 30+ meta-analyses, and multiple landmark RCTs including REDUCE-IT (N=8,179), VITAL (N=25,871), and the recently published PISCES trial (NEJM 2026, N=1,228 hemodialysis patients showing 43% CV event reduction). Omega-3s have the strongest evidence for triglyceride reduction (20-50%, dose-dependent), cardiovascular secondary prevention in high-risk populations, rheumatoid arthritis symptom relief, dry eye improvement, preterm birth prevention, and adjunctive depression treatment (EPA-dominant formulations).

Key distinctions: EPA is more anti-inflammatory and better for mood; DHA is more structural and critical for brain and retinal tissue. Formulation matters substantially — re-esterified triglyceride (rTG) forms have 70-95% bioavailability vs 20-40% for ethyl esters (EE) on low-fat meals. Plant-based ALA converts to EPA at only 5-10% and to DHA at <5%, making direct marine-source EPA/DHA far more efficient.

The primary safety concern is atrial fibrillation/flutter at high doses (HR 1.5 with 4g/d icosapent ethyl in REDUCE-IT), though real-world rates are 1/3 to 1/5 of trial rates. Bleeding risk is theoretical at standard doses — large RCTs show no significant increase in major bleeding even at 4g/d. The therapeutic window is wide (1-4g/d therapeutic; no reports of serious toxicity from supplementation).

Indications & Evidence

Reading this table: Stars = evidence volume. Type = what kind of evidence (see legend). BH = Bradford Hill causal strength (/9). Safety = FAERS/trial signals for THIS specific indication. One row = one decision.

Hard rule: Star rating cannot exceed the causal taxonomy ceiling for its Type. E.g., Type=AHE (animal-to-human) caps at 2/5 regardless of how many animal studies exist.

Type codes: DC=Direct causation | PC=Probable | UCC=Unreplicated causal | BC=Biomarker correlation | SE=Surrogate endpoint | ME=Mechanistic extrapolation | AHE=Animal-to-human | OA=Observational | RC=Reverse causation | CF=Confounded | FA=Folk/anecdotal | NE=No evidence BH: Bradford Hill criteria met (of 9). 7-9=strong causal | 5-6=moderate | 3-4=weak | 1-2=speculative | 0=none Safety flags: -- No signals | MON Monitor (known AEs, manageable) | WARN FAERS or trial safety signal | AVOID Contraindicated for this specific indication

Star rating legend:

Prescribing

Dosing Table

Upper limits: FDA GRAS ≤3g/d | EFSA ≤5g/d safe | >3g/d under medical supervision

Formulation Table

Clinical pearl: EE forms taken on low-fat meals lose 50-70% bioavailability. Many "negative" omega-3 trials used EE without controlling fat intake. The rTG form offers the best true cost per absorbed omega-3 ($35/mo effective vs $50/mo for EE after bioavailability adjustment).

Condition-Specific Protocols

Hypertriglyceridemia Protocol

Evidence: 5/5 | PMID: 30415628, 31422671

Phase 1: Initiation (Weeks 1-4)

• Dose: 2g EPA+DHA daily, split with 2 meals containing ≥10g fat each
• Monitor: Baseline lipid panel, liver enzymes
• Goal: Establish tolerance, assess GI side effects

Phase 2: Therapeutic (Weeks 4-12)

• Dose: Escalate to 3-4g EPA+DHA daily if TG >250 mg/dL (or Rx icosapent ethyl 4g/d)
• Monitor: Lipid panel at 8-12 weeks; LDL may rise 5-10 mg/dL (acceptable if TG normalizes)
• Expected: TG reduction 20-30% at 2g/d; 40-50% at 4g/d from baseline >250

Phase 3: Maintenance (Week 12+)

• Dose: Maintain effective dose; may reduce to 2g/d if TG normalized
• Monitor: Lipid panel every 6-12 months; Omega-3 Index annually
• Reassess: If TG <50 mg/dL, reduce dose

Stop/Reassess: Non-response at 12 weeks (TG reduction <15%); significant GI intolerance; new AF symptoms

CV Secondary Prevention Protocol

Evidence: 5/5 | PMID: 30415628, 32114706, 41201837

Dose: 1-2g EPA+DHA daily (general); 4g EPA daily (icosapent ethyl) for statin-treated patients with TG ≥150 and established CVD or diabetes Duration: Lifelong Monitor: Lipid panel every 6-12 months; ECG if new palpitations (AF screening) Drug timing: Safe with statins (additive TG benefit). If on warfarin: check INR at 2 weeks Expected: 8-25% reduction in major CV events over 1-5 years (varies by risk profile) AF caution: High-dose IPE (4g/d) associated with AF/flutter HR 1.5 in REDUCE-IT; higher risk with prior AF history. Use lower doses (1-2g/d) if AF history.

Rheumatoid Arthritis Protocol

Evidence: 5/5 | PMID: 29271993, 7639811

Dose: 2.7-3g EPA+DHA daily (EPA-rich formulations preferred), split 2-3x with meals Duration: Minimum 12 weeks to assess; 6 months for maximum benefit Monitor: CRP, ESR, DAS28 every 3 months; NSAID usage log Expected: Morning stiffness reduced 30-40 min; tender joints -15-25%; 30-40% may reduce NSAID dose Drug safety: Safe with methotrexate, biologics (anti-TNF), corticosteroids. May allow NSAID dose reduction.

Safety

Interactions Table

Clinical pearl: Despite theoretical bleeding concerns, REDUCE-IT (4g EPA, N=8,179) and VITAL (1g omega-3, N=25,871) showed no significant increase in major bleeding even in patients on aspirin.

Contraindications

• Absolute: Fish/shellfish allergy (use algal oil); active uncontrolled bleeding disorder; hemorrhagic stroke <3 months; scheduled surgery <7 days
• Relative: eGFR <30 (caution with high doses); triple antithrombotic therapy; bipolar disorder (high-dose may trigger mania — rare); prior AF (use lower doses)

Adverse Effects

FAERS Signal Table (from BioMCP)

FAERS context: For OTC fish oil/omega-3 supplements, FAERS data is dominated by concomitant medication noise (fatigue, headache, arthralgia at thousands of reports) — these reflect the sick populations taking fish oil alongside other medications, not omega-3 causation. Only the prescription products (VASCEPA, LOVAZA) have signal-level FAERS data. The AF/flutter and bleeding signals from VASCEPA are the only clinically meaningful FAERS findings.

Monitoring Table

Special Populations

Renal Impairment

Hepatic Impairment

Pregnancy & Lactation

• Safety: Extensively studied; no teratogenic effects. FDA safe. Reduces preterm birth 11% (Cochrane, 70 RCTs, N=19,927).
• Dose: 300-600mg DHA daily; DHA-dominant formulations preferred (2:1 or 3:1 DHA:EPA)
• Form: TG or rTG preferred (better tolerated). Algal DHA for fish-averse.
• Avoid: Cod liver oil (excess vitamin A is teratogenic); high-mercury fish

Synergies & Stacking

Individual Response Modifiers

Sex-Specific Considerations

Genetic Modifiers

Community & Anecdotal Evidence

Disclaimer: This section captures real-world user reports from online communities. None of this constitutes clinical evidence. N-sizes are approximate. Selection bias, placebo effect, and recall bias are inherent. Presented for completeness, not as medical guidance.

Dominant Sentiment

Positive-to-mixed across ~10,000+ posts/threads. Omega-3 is treated as a "foundational baseline supplement" across r/Nootropics, r/Supplements, r/longevity, Longecity, and biohacker circles. ~60% strongly positive, ~25% cautiously positive, ~10% skeptical ("eat fish instead"), ~5% negative.

What Users Report

Community Dosing vs Clinical

Popular Stacks (Community)

Red Flags & Skepticism Notes

• MLM involvement: No major MLM companies dominate fish oil (unlike collagen, CBD). Normal retail distribution.
• Influencer concentration: Broadly recommended across many voices (Rhonda Patrick, Peter Attia, David Sinclair, etc.) — not concentrated in one promoter.
• Astroturfing signals: Some "best fish oil brands" articles on Medium/TechBullion are thinly disguised affiliate content. Suspicious single-brand promotion on Reddit detected but not systematic.
• Commercial bias: Fish oil industry is ~$4B globally. Nordic Naturals and others fund studies — researcher independence is a consideration for brand-specific (not class-level) claims.
• Quality crisis: GWU study found 45% of tested supplements were rancid. Only 9% contained enough EPA/DHA to lower triglycerides. IFOS certification is community gold standard.

Folk vs Clinical Reality Check

Community experience aligns with clinical data on: joint pain relief, triglyceride reduction (lab-verified), dry eye improvement, and mood stabilization (at EPA-dominant doses). Community diverges on: cognitive enhancement in healthy adults (clinical evidence weak), "everyone should take it" (VITAL showed no general-population CV benefit at 1g/d), and the magnitude of rTG superiority over EE (community overstates the practical difference when EE is taken properly with fat). The ~1-3% paradoxical mood worsening is clinically plausible in bipolar-spectrum individuals and is consistent with rare case reports.

Deep Dive: Mechanisms & Research

Key Mechanisms (Ataraxia-Vetted)

1. Eicosanoid Modulation (Clinical Translation: YES) EPA competes with arachidonic acid (AA) for COX and LOX enzymes, producing less inflammatory 3-series prostaglandins (PGE3) and 5-series leukotrienes (LTB5). This directly reduces inflammatory signaling and is the primary mechanism behind RA, CVD, and anti-inflammatory benefits. Inhibits NF-kB transcription factor, reducing TNF-alpha, IL-1beta, IL-6.

2. Specialized Pro-Resolving Mediators — SPMs (Clinical Translation: PARTIAL) EPA and DHA are precursors to resolvins, protectins, and maresins that actively "turn off" inflammation by promoting macrophage clearance and reducing neutrophil infiltration without immunosuppression. Expert consensus (PMID 38805158) confirms SPMs in inflammation resolution and muscle preservation. Direct SPM supplementation is an emerging research frontier.

3. Membrane Incorporation (Clinical Translation: YES) EPA and DHA incorporate into phospholipid bilayers, increasing membrane fluidity. DHA comprises 40% of brain polyunsaturated fatty acids and is critical for neuronal membrane function, synaptic plasticity, and receptor signaling. This underlies the DHA-specific benefits for brain and retinal tissue.

4. Triglyceride Reduction (Clinical Translation: YES) Reduces hepatic VLDL synthesis and increases lipoprotein lipase activity. This is the best-established pharmacological mechanism — 2-4g/d produces 20-50% TG reduction dose-dependently. Underpins FDA approval for hypertriglyceridemia.

5. Circadian Clock Regulation (Clinical Translation: EMERGING) Novel discovery (PMID 40347940): DHA/EPA target RORalpha to regulate circadian clock oscillations, facilitating BMAL1 nuclear translocation in hypothalamic neurons. This links omega-3 to sleep and circadian biology — a previously unknown mechanism with implications for T2D-related sleep impairment.

6. FFAR4 Activation (Clinical Translation: PARTIAL) Marine omega-3 activates free fatty acid receptor 4 (FFAR4/GPR120), reducing inflammatory markers in PBMCs (PMID 41373925). Mediates anti-inflammatory effects in adipose tissue and contributes to metabolic benefits.

Pharmacokinetics

• Absorption: Via lymphatic system (chylomicrons), bypassing hepatic first-pass. 40-95% depending on formulation and dietary fat.
• Tissue incorporation: Gradual over days-weeks. RBC Omega-3 Index plateaus at 3-4 months.
• Half-life: 24-48h plasma; tissue incorporation ongoing for weeks.
• Metabolism: Beta-oxidation in mitochondria; liver uses for VLDL synthesis and SPM production. Brain, heart, retina preferentially accumulate DHA. EPA more readily oxidized for energy.
• ALA conversion: Delta-6-desaturase (rate-limiting, competes with omega-6). Only 5-10% to EPA, <5% to DHA. Cofactors: B6, Biotin, Magnesium, Zinc, Vitamin-C.

Clinical Trials (from BioMCP / ClinicalTrials.gov)

Registry counts: 1,007 registered (condition "omega-3"), 666 completed, 46 recruiting, 76 recruiting (intervention "fish oil").

Regulatory Status (from BioMCP)

• FDA: Vascepa (icosapent ethyl) — NDA approved for severe hypertriglyceridemia + CV risk reduction. Multiple generics (Apotex, Hikma, Dr. Reddy's, Teva, Qilu 2024, Pharmobedient 2024). Lovaza (omega-3-acid ethyl esters) — NDA approved for severe hypertriglyceridemia. OTC fish oil — GRAS up to 3g/d EPA+DHA.
• EMA: Vazkepa (icosapent ethyl) authorized (EMEA/H/C/005398). Lovaza — no EMA record.
• Regulatory context: Omega-3 as a class straddles supplement (OTC) and pharmaceutical (Rx) categories. The Rx products command patent-protected pricing for the same EPA/DHA available OTC at lower cost. Post-patent generic flooding (5+ VASCEPA ANDAs) is driving product quality complaints in FAERS (odor, physical issues) — a manufacturing quality concern, not a compound safety issue.

Ataraxia Verdict (as of 2026-04-17)

Evidence Classification (Mode 5: Evidence Classifier)

Hype Check (Mode 1: Fallacy Radar)

• Appeal to nature: Minor — "natural TG form" marketing overstates clinical significance of formulation differences
• Cherry-picking: REDUCE-IT is prominently cited while STRENGTH (negative) gets less airtime. Both are relevant.
• Hasty generalization: REDUCE-IT (high-dose EPA in statin-treated, elevated-TG patients) is often extrapolated to general population benefit — VITAL showed no such effect at 1g/d.
• Argument from popularity: "Most studied supplement" is true but doesn't make every claimed benefit valid
• Overall: Omega-3 has genuine strong evidence for specific indications. The hype is mostly about overgeneralizing from high-risk populations to everyone.

Evidence Gaps

• Optimal omega-6:omega-3 ratio remains undefined (targets range from 1:1 to 4:1)
• FADS1/FADS2 genotype-guided dosing not established despite clear biological mechanism
• Long-term cognitive protection: conflicting data; larger, longer trials needed
• Formulation head-to-head trials scarce (few rTG vs TG vs EE direct comparisons)
• AF mechanism at high doses unclear — dose-dependent? Form-dependent? EPA-specific?
• Pediatric dosing poorly established across age groups
• SPM direct supplementation — will resolvins/protectins outperform parent omega-3s?
• Individual variability in response: genetic and microbiome contributors unknown

Bias Flags (Mode 4: First Principles)

• Fish oil industry (~$4B global) funds research — brand-specific claims should be scrutinized more than class-level evidence
• Prescription omega-3 manufacturers (Amarin/VASCEPA) have strong financial incentive to promote EPA-only over mixed EPA/DHA
• The mineral oil placebo in REDUCE-IT raised legitimate concerns about inflated effect size (mineral oil may have worsened the placebo group's lipids)
• "Omega-3 Index testing" is promoted by OmegaQuant (founded by omega-3 researcher William Harris) — potential conflict of interest, though the biomarker itself is validated

Manipulation Flags (Mode 2: Manipulation Shield)

• Industry marketing: "Clinical strength" labeling on OTC products containing only 300mg EPA+DHA per capsule (inadequate for most therapeutic effects). "1000mg fish oil" prominently displayed when EPA+DHA content is 300mg — deliberately misleading.
• Influencer economics: Broad-based recommendations from multiple credible voices (not concentrated). Affiliate revenue is modest compared to other supplement categories. No red-flag influencer concentration.
• Counter-narrative manipulation: Some statin-industry-adjacent messaging dismisses omega-3 benefits — cui bono for statin manufacturers if omega-3 reduces CV events independently.
• Cui bono summary: Fish oil manufacturers win if you supplement daily. Rx omega-3 makers (Amarin) win if you use expensive prescription EPA over OTC. Statin manufacturers lose market positioning if omega-3 provides independent CV benefit. OmegaQuant wins if testing becomes standard. The consumer wins if they use evidence-based dosing of quality-tested products.
• Red team highlight: The most concerning angle is quality — 45% of tested products being rancid means many users are taking oxidized PUFA that may be pro-inflammatory. The industry's quality control problem undermines even the strong evidence base.

Decision Support (Mode 3: Clarity Compass)

• Health utility score: 9/10 — one of the best-evidenced supplements in existence, with landmark RCTs confirming benefit for triglyceride reduction, CV secondary prevention, RA, dry eye, preterm birth, adjunctive depression, and 2026 PISCES CV benefit in hemodialysis; very broad indication breadth.
• Opportunity cost: Very low — affordable ($15-40/mo), well-tolerated, wide therapeutic window, minimal interaction concerns
• Verdict: ADD — for individuals with any of: cardiovascular risk factors, inflammatory conditions, inadequate fish intake (<2 servings/wk), elevated triglycerides, or Omega-3 Index <8%
• Conditions: Test Omega-3 Index before and 3-4 months after starting. Use IFOS-certified rTG form. Take with fatty meals. Monitor lipids if using for TG reduction. Caution with doses >2g/d if history of AF.

Bottom Line

Omega-3 EPA/DHA is one of the best-evidenced supplements in existence, with 120+ PMIDs, 30+ meta-analyses, and multiple landmark RCTs confirming benefit for triglyceride reduction, cardiovascular secondary prevention, rheumatoid arthritis, dry eye, preterm birth prevention, and adjunctive depression treatment. The 2026 PISCES trial (NEJM) extends CV benefit to hemodialysis. The evidence does NOT support general-population CV prevention at standard doses (VITAL), Alzheimer's treatment, cancer prevention, or weight loss. The primary safety signal is AF/flutter at high-dose EPA (4g/d), with real-world rates well below trial rates. Quality is a genuine concern — IFOS certification and rTG formulation are the pragmatic answers. For most health-conscious adults, 1-2g EPA+DHA daily from a quality rTG product, taken with fatty meals, is well-supported by evidence and low-risk.

Practical Notes

Brands & Product Selection

Quality markers: IFOS 5-star (gold standard), USP verified, NSF certified, ConsumerLab approved. Request CoA if not displayed. TOTOX value <26 (lower = fresher). Mercury <0.1 ppm. Check EPA+DHA amounts — not just "fish oil 1000mg."

Premium (IFOS 5-star): Nordic Naturals, OmegaVia, Sports Research, Viva Naturals Mid-tier (USP/NSF): Nature Made, Kirkland Signature (best value), NOW Foods, Life Extension Algal: Nordic Naturals Algae Omega, Ovega-3, Sports Research Algae Oil Rx: Vascepa (icosapent ethyl, EPA-only), Lovaza (EPA+DHA ethyl esters), Epanova (FFA form)

Red flags: No third-party certification; no EPA/DHA amounts on label; price <$10/30-day; strong rancid smell; "proprietary blend"; MLM distribution.

Storage & Handling

• Optimal: Refrigerate or freeze for longest shelf life; taking frozen capsules dramatically reduces fishy burps
• Acceptable: Room temperature (15-25C) if used within 6 months
• Avoid: Bathroom storage (humidity); direct sunlight; clear plastic containers
• Shelf life: Unopened 2-3 years; opened 3-6 months (refrigerate to extend to 6-9 months); liquid 2-3 months after opening
• Spoilage signs: Rancid/strong fishy odor (cut capsule open to check); cloudy/darkened oil; capsule deterioration. Discard rancid oil — oxidized omega-3 may be pro-inflammatory.

Palatability & Compliance

• Freeze capsules before taking — eliminates fishy burps for most people
• Enteric-coated versions reduce reflux (don't improve bioavailability)
• Liquid forms: mix with juice, smoothies, or yogurt; avoid hot beverages (heat damages omega-3)
• Krill oil and algal oil have no fishy aftertaste
• The #1 determinant of efficacy is consistency — choose a tolerable form you'll actually take daily

Exercise & Circadian Timing

• No strong circadian preference; choose timing based on fatty meal schedule
• Post-workout meals provide adequate fat for absorption
• Anti-inflammatory benefits accumulate over weeks, not acute — timing relative to exercise doesn't matter acutely
• New evidence (PMID 40347940): DHA/EPA regulate circadian clocks via RORalpha — theoretical basis for consistent daily timing

Reference Ranges (Expected Biomarker Changes)

Cost

True cost formula: Price / (servings x EPA+DHA x bioavailability). rTG at $30/mo with 85% bioavailability = $35/mo absorbed. EE at $20/mo with 40% bioavailability = $50/mo absorbed. rTG is actually cheaper per absorbed omega-3.

What We Don't Know

• Whether genotype-guided dosing (FADS1/FADS2, APOE) would improve individual outcomes
• Optimal omega-6:omega-3 ratio for health (current targets range 1:1 to 4:1 — none validated by RCTs)
• Why some individuals respond robustly while others show minimal benefit
• Whether EPA-only (REDUCE-IT model) is genuinely superior to mixed EPA/DHA for CV prevention, or if the mineral oil placebo confounded REDUCE-IT
• Whether direct SPM supplementation (resolvins, protectins) will outperform parent omega-3s
• The mechanism and dose-dependence of the AF/flutter signal at high doses
• Whether omega-3 from whole fish provides benefits beyond what supplements can match
• Long-term effects of high-dose supplementation (>4g/d) beyond 5 years
• How omega-3s interact with the gut microbiome to mediate health effects
• Whether the circadian clock regulation mechanism (RORalpha/BMAL1) translates into sleep quality improvements in non-diabetic populations
• Whether omega-3 truly has no bone benefit (VITAL negative at 1g/d) or whether higher doses might help
• How krill oil's phospholipid structure compares to TG forms for brain DHA delivery in humans
• Sex-specific pharmacokinetics and optimal dosing differences

References

Systematic Reviews & Meta-Analyses

1. Abdelhamid AS et al. (2020). Omega-3 for CV prevention. Cochrane Database Syst Rev. 86 RCTs, N=162,796. Modest CV mortality reduction RR 0.92. PMID: 32114706
2. Middleton P et al. (2018). Omega-3 in pregnancy. Cochrane Database Syst Rev. 70 RCTs, N=19,927. Preterm birth -11%. PMID: 30480773
3. Grosso G et al. (2014). Omega-3 for depression. PLoS One. 13 RCTs, N=1,233. EPA-rich SMD -0.38. PMID: 24805797
4. Brown TJ et al. (2019). Omega-3 for T2D. BMJ. No glycemic benefit; TG reduction. PMID: 31434641
5. Deinema LA et al. (2017). Omega-3 for dry eye. 17 RCTs, N=3,363. Significant benefit. PMID: 28114855
6. Miller PE et al. (2014). BP meta-analysis. 70 RCTs, N=4,973. SBP -3.5 mmHg. PMID: 25099542
7. Bloch MH, Qawasmi A (2011). ADHD meta-analysis. 10 RCTs. Small benefit d=0.2-0.3. PMID: 21784145
8. Cochrane RA review (2017). 17 RCTs, N=823. Pain SMD -0.24. PMID: 29271993
9. Scorletti E et al. (2014). NAFLD. 18 RCTs, N=1,424. Liver fat -15-30%. PMID: 25065357
10. Duarte-Garcia A et al. (2020). SLE meta-analysis. 5 RCTs, N=276. Moderate benefit. PMID: 33131703
11. Omega-3 for AMD (2026). J Nutr. OR 0.82; nAMD OR 0.57; GA OR 0.65. PMID: 41482231
12. Omega-3 in hemodialysis (2026). Clin Nutr ESPEN. Anti-inflammatory safety confirmed. PMID: 41692069
13. CV risk metabolic markers (2026). Nutr Metab Cardiovasc Dis. Diverse populations. PMID: 41494879
14. Omega-3 for NAFLD/MASLD in adults (2025). Updated MA. PMID: 40441053
15. Vascular health FMD (2026). Optimal ~1650mg EPA + 750mg DHA. PMID: 41493572
16. Muscle protein synthesis (2024). MA: omega-3 enhances MPS. PMID: 38777807
17. Bleeding risk meta-analysis (2024). J Am Heart Assoc. Quantified bleeding across RCTs. PMID: 38742535
18. High-dose omega-3 for migraine (2024). Adv Nutr. NMA: superior to standard prophylaxis. PMID: 38110000
19. Omega-3 for pediatric depression (2024). Cochrane. PMID: 39564892
20. Dose-response cognition (2024). BMC Med. Korean group. PMID: 38468309
21. Androgenetic alopecia NMA (2026). Includes omega-3. PMID: 41561175

Landmark RCTs

22. Bhatt DL et al. (2019). REDUCE-IT. NEJM. N=8,179. 4g EPA reduced CV events 25%. PMID: 30415628
23. Manson JE et al. (2019). VITAL. NEJM. N=25,871. MI -28%; no total CV benefit. PMID: 30415637
24. PISCES trial (2026). NEJM. N=1,228. Fish oil reduced serious CV events 43% in hemodialysis. PMID: 41201837
25. Pediatric depression RCT (2026). JAMA Netw Open. N=257. NEGATIVE: no benefit. PMID: 41481294
26. VITAL bone/fracture (2026). JBMR. N=25,871. No fracture reduction. PMID: 41603552
27. Stress/anxiety/depression/sleep RCT (2026). J Affect Disord. N=64. Positive multi-domain. PMID: 41461240
28. Krill oil for knee OA (2024). JAMA. NEGATIVE: not superior to placebo. PMID: 38776073
29. Krill oil muscle strength in elderly (2025). Similar across sexes. PMID: 41344001

Mechanism & Bioavailability

30. Calder PC (2015). Anti-inflammatory mechanisms. BBA. PMID: 25149823
31. Cholewski M et al. (2018). Chemistry and bioavailability review. Nutrients. PMID: 30400360
32. Alijani S et al. (2025). EPA/DHA bioavailability comprehensive review. Prog Lipid Res. PMID: 39736417
33. Sleep/circadian regulation (2025). Cell Rep Med. DHA/EPA → RORalpha → BMAL1. PMID: 40347940
34. SPM expert consensus (2024). FASEB J. Resolution of inflammation. PMID: 38805158
35. FFAR4 activation (2025). Nutrients. EPICO trial. PMID: 41373925

Safety & Pharmacogenomics

36. Harris WS (2007). Bleeding concerns. Am J Cardiol. PMID: 17368278
37. IPE FAERS analysis (2023). AF confirmed; bleeding only with antithrombotics. PMID: 37873598
38. Real-world IPE safety (2024). RWE rates 1/3-1/5 of trial. PMID: 40148153
39. FADS1/FADS2 polymorphisms (2026). Erythrocyte FA composition. PMID: 41441000
40. FADS1 mitochondrial function (2024). PMID: 39218219
41. Multi-level FADS gene-diet interaction (2025). PMID: 40405463
42. APOE and omega-3 cognition (2023). PMID: 37890592

Disease-Specific

43. Kremer JM et al. (1995). RA: omega-3 allowed NSAID discontinuation. PMID: 7639811
44. Fortin PR et al. (1995). RA: 3g/d reduced NSAID use 40%. PMID: 7543475
45. Kangari H et al. (2013). Dry eye improvement. PMID: 23818447
46. Quinn JF et al. (2010). Alzheimer's: DHA NEGATIVE. PMID: 20966004
47. Yurko-Mauro K et al. (2010). MCI: DHA improved memory. PMID: 21046153
48. Sublette ME et al. (2011). Depression: EPA ≥60% effective. PMID: 21939614
49. Chang JP et al. (2019). ADHD: omega-3 improves attention. PMID: 30851075
50. Miles EA, Calder PC (2021). Omega-3 and childhood allergic disease. PMID: 33668905
51. Simopoulos AP (2002). Omega-3 in autoimmune disease. PMID: 12480795
52. Calder PC (2013). Omega-3 and inflammation. PMID: 22765297

Guidelines (2024-2026)

53. ACC 2025 CV inflammation statement. PMID: 41020749
54. ISSN 2025 omega-3 position stand. PMID: 39810703
55. International preterm birth consensus (2024). PMID: 38070679
56. ESPEN 2024 dementia nutrition guideline. PMID: 38772068
57. Japanese Critical Care Nutrition Guideline 2024. PMID: 40119480
58. MAFLD dietary consensus (2024). PMID: 39270816
59. EPA severe mental illness guidance (2024). PMID: 39655999

Additional Key References

60. Ghasemifard S et al. (2014). Bioavailability review. PMID: 25218856
61. Dyerberg J et al. (2010). Formulation bioavailability. PMID: 20638827
62. Parker HM et al. (2012). NAFLD: 4g/d reduced liver fat 30%. PMID: 22633978
63. Thien FC et al. (2002). Asthma Cochrane. No consistent benefit. PMID: 12076426
64. Carlson SE et al. (2013). Prenatal DHA visual development. PMID: 23426033
65. Cabo J et al. (2012). BP in older adults. PMID: 22611253
66. Skulas-Ray AC et al. (2019). AHA advisory on omega-3 for TG. PMID: 31422671
67. Omega-3 and arrhythmias (2024). Circulation. EPA vs DHA AF risk. PMID: 39102482
68. Prenatal fish oil and eczema genetics (2024). JAMA Dermatol. PMID: 39196551
69. Korea rTG-omega-3 for meibomian gland (2024). PMID: 39907215
70. Taiwan late-life depression prevention (2024). PMID: 39306009
71. Mortality in cancer survivors (2026). 24% lower all-cause. PMID: 41855738
72. CKM syndrome mortality (2026). NHANES. L-shaped threshold. PMID: 41532525
73. UK Biobank omega-6:omega-3 ratio and mortality (2024). PMID: 38578269
74. Diabetic retinopathy risk (2025). PMID: 40987202
75. Schizophrenia updated MA (2025). PMID: 41219779